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The International Association for the Study of 
Pain (IASP) defines pain as “an unpleasant sen-
sory and emotional experience associated with 
actual or potential tissue damage, or described in 
terms of such damage” [1]. There is, however, no 
one accepted definition of chronic postsurgical 
pain and it is debatable whether, at the present 
time, a single definition would be useful [2]. 
Most attempts at defining chronic postsurgical 
pain, whether general [3] or specific to a surgi-
cal procedure [4,5], are descriptive in nature and 
offer a time frame for chronicity beginning 2 
or 3 months after surgery. Macrae and Davies 
propose the following four-point definition of 
chronic postsurgical pain: “the pain developed 
after a surgical procedure; the pain is of at least 
2 months duration; other causes for the pain 
have been excluded; the possibility that the pain 
is continuing from a pre-existing problem should 
be explored and exclusion attempted” [2].
Most patients who undergo surgery recover 
uneventfully and resume their normal daily 
activities within weeks. However, chronic post-
surgical pain develops in an alarming propor-
tion of patients. The magnitude of the problem 
is evidenced by recent epidemiological data doc-
umented later. A fact that is rarely appreciated 
by pain clinicians and researchers is that every 
chronic postinjury or post surgical pain was once 
acute; the development of chronic postsurgical 
pain involves a transitional process. The tradi-
tional, dominant focus on studying established 
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Most patients who undergo surgery recover uneventfully and resume their normal daily 
activities within weeks. Nevertheless, chronic postsurgical pain develops in an alarming 
proportion of patients. The prevailing approach of focusing on established chronic pain 
implicitly assumes that information generated during the acute injury phase is not important 
to the subsequent development of chronic pain. However, a rarely appreciated fact is that 
every chronic pain was once acute. Here, we argue that a focus on the transition from acute 
to chronic pain may reveal important cues that will help us to predict who will go on to develop 
chronic pain and who will not. Unlike other injuries, surgery presents a unique set of 
circumstances in which the precise timing of the physical insult and ensuing pain are known 
in advance. This provides an opportunity, before surgery, to identify the risk factors and 
protective factors that predict the course of recovery. In this paper, the epidemiology of chronic 
postsurgical pain is reviewed. The surgical, psychosocial, socio–environmental and patient-
related factors that appear to confer a greater risk of developing chronic postsurgical pain are 
described. The genetics of chronic postsurgical pain are discussed with emphasis on known 
polymorphisms in human genes associated with chronic pain, genetic studies of rodent models 
of pain involving surgical approaches, the importance of developing accurate human chronic 
postsurgical pain phenotypes and the expected gains for chronic postsurgical pain medicine 
in the post-genomic era. Evidence is then reviewed for a preventive multimodal analgesic 
approach to surgery. While there is some evidence that chronic postsurgical pain can be 
minimized or prevented by an analgesic approach involving aggressive perioperative multimodal 
treatment, other studies fail to show this benefit. The transition of acute postoperative pain 
to chronic postsurgical pain is a complex and poorly understood developmental process, 
involving biological, psychological and social–environmental factors.
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chronic pain misses important cues that may help us to predict 
who will go on to develop chronic postsurgical pain and who 
will recover uneventfully. Emphasis on identifying the processes 
that underlie the transition to chronicity has been a neglected 
topic of investigation. The aim of this review is to critically 
examine the factors that are associated with the development of 
chronic postsurgical pain. We first review available data on the 
epidemiology and course of chronic postsurgical pain following 
various surgical procedures. We then describe the surgical, psy-
chosocial, social–environmental and patient-related factors that 
appear to confer a greater risk of developing chronic postsurgical 
pain. We also discuss the genetics of chronic postsurgical pain, 
with an emphasis on known polymorphisms in human genes 
associated with chronic pain in general, pain genetic studies of 
rodent models involving surgical approaches, the importance of 
developing accurate human pain phenotypes and the expected 
gains for chronic postsurgical pain medicine in the postgenomic 
era. Finally we review the evidence suggesting that a preventive 
analgesic approach can reduce the incidence and intensity of 
chronic postsurgical pain. We conclude with key issues, an expert 
commentary and a 5-year view into the future. 
Epidemiology of chronic postsurgical pain
Table 1 shows the incidence of chronic postsurgical pain follow-
ing a variety of surgical procedures, including limb amputation, 
thoracotomy, mastectomy, hernia repair, open cholecystectomy, 
cesarean section, hip replacement and median sternotomy for 
coronary artery bypass graft surgery. This table illustrates 
the growing awareness of chronic postsurgical pain [6–9]. For 
example, a prospective study of approximately 5000 patients 
estimated the incidence of acute neuropathic pain in the days 
after surgery to be between 1 and 3% [10]. A 1-year follow-up 
showed that 56% of the patients with acute neuropathic pain 
continued to have pain [10]. Other reports suggest the incidence 
of acute postsurgical neuropathic pain is considerably higher [11] 
and, given the 56% rate of conversion to chronicity [11], support 
the view that up to 10% of patients report severe, intractable 
chronic postsurgical pain 1 year after surgery. These statistics 
are staggering, especially when one considers the total number 
of patients worldwide who undergo surgery each year. It is not 
at all surprising, then, to see that almost 25% of more than 
5000 patients referred to chronic pain treatment centers have 
chronic postsurgical pain [12]. 
We know next to nothing about pain beyond the 1-year mark. 
Most studies followed patients for approximately 1 year after sur-
gery. The data show the 1-year incidence to be highly variable and 
surgery specific, ranging from a low of approximately 10–15% 
following modified radical mastectomy [13] to a high of 61–70% 
for thoracotomy [14] and amputation [15]. Follow-up beyond the 
1-year mark is not common but there are two studies of patients 
followed for up to 5 or 6 years after hernia repair and two stud-
ies of lower limb amputees followed for 2 years. The longer term 
hernia repair follow-up data indicate that pain persists in 8.1–19% 
of patients for up to 6 years, with severe or very severe pain occur-
ring in 1.8%. A total of 2 years after amputation approximately 
60% of amputees report phantom limb pain (PLP) and 21–57% 
report stump (residual limb) pain [16,17]. These studies indicate 
that even the lowest incidences are unacceptably high.
Some of the variability in these estimates can be accounted for 
by the criterion used to classify patients as having chronic pain; the 
more stringent the criterion, the lower the estimate. For example, 
studies that measure the intensity of pain or the impact of pain 
on daily activities show that the incidence of chronic postsurgical 
pain is lower when the cut-off for severity and impact of pain is 
high [14–16,18–21]. Other reasons for the variability in estimates for 
a given surgical procedure include lack of precision in defining/
diagnosing chronic postsurgical pain, sampling method, source of 
patients, their genetic background and whether the classification 
of the pain as chronic was by self-report. Despite this variability, 
even the most conservative estimates are a cause for concern. 
Factors associated with chronic postsurgical pain
Surgical factors associated with chronic postsurgical pain
The following surgical factors are associated with an increased 
likelihood of developing chronic postsurgical pain: increased 
duration of surgery [22,23], low (vs high) volume surgical unit [13], 
open (vs laparoscopic) approach [24], pericostal (vs intracostal) 
stitches [25], conventional hernia repair [24] and intraoperative 
nerve damage [10,24]. Whether these factors are causally related 
to the development of chronic pain is not known. However, these 
factors appear to have in common greater surgical trauma and, 
in particular, they point to intraoperative nerve injury as a likely 
causal mechanism. Nerve damage produces acute and lasting 
changes in the injured nerves, and even in their intact neighboring 
nerves, pain pathways in the CNS, and motor and sympathetic 
outputs (reviewed by Devor and Seltzer [26]). These changes are 
probably the main culprit in producing both acute and chronic 
neuropathic pain. 
More than 30 years of basic science research has shown that 
nerve injury produces neuropathic conditions and behaviors in 
rodents that resemble symptoms of chronic neuropathic pain in 
humans (for reviews see [27,28]). In fact, the most commonly used 
animal models of neuropathic pain involve intentional damage 
to peripheral nerves [29–32] or spinal nerves [33], by total nerve 
section [29,32,33], or partial nerve ligation [31] or constriction [30]. 
Using these models enabled investigators to identify a number 
of intraoperative methodological factors. The type of knife that 
was used when cutting tissues and nerves affected neuropathic 
pain-related behavior in a rodent model of limb amputation pains 
and anesthesia dolorosa. Electrocautery was associated with sig-
nificantly more chronic pain than was use of a laser [34]. In a 
model of brachial plexus avulsion following hindpaw deafferenta-
tion, it was found that using ketamine and xylazine for general 
anesthesia significantly reduced the incidence of neuropathic pain 
when compared with anesthesia using a barbiturate, suggesting 
that improvements in the type of general anesthetic used during 
surgery may reduce pain chronicity [35]. 
One of the triggers of pain chronicity is thought to be the amount 
of injury discharge produced intraoperatively and its impact on the 
CNS. When a peripheral nerve is transected or otherwise injured, 
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Table 1. Incidence of chronic postsurgical pain following various surgical procedures.
Study Surgical procedure Patients with data 
in study (n)
Follow-up time 
(postoperation)
Incidence of chronic postsurgical pain 
(%)
Ref.
Tasmuth et al. 
(1997)
MRM or BCT with 
axillary clearance
93
MRM = 53
BCT = 40
1 year Breast region:
MRM = 17
BCT = 33
Ipsilateral arm:
MRM = 13
BCT = 23
[96]
Aasvang et al. 
(2006)
Hernia repair 694 1 year Inguinal pain = 56.6
Ejaculation pain = 18.3
Pain in:
Testes = 39.7
Shaft = 5.4
Glans = 4.5
Thigh = 11.6
[202]
Grant et al. 
(2004)
Hernia repair 5 years Groin pain = 19
Severe or very severe groin pain = 1.8
Testicular pain = 16.1
[21]
Bay-Nielsen 
et al. (2001)
Aasvang et al. 
(2006)
Hernia repair 1166 1 year
6.5 years
Pain in groin area = 28.7
Pain interfering with work or leisure = 11
Chronic inguinal pain = 8.1
[20]
[203]
Katz et al. 
(1996)
Thoracotomy 23 1.5 years Dull, aching or burning pain on a daily to 
weekly basis = 52
Mean pain intensity: 3.3/10
[94]
Pertunnen 
et al. (1999)
Thoracotomy 67 1 year Posthoracotomy pain = 61 
Severe pain = 3–5 
[14]
Gotoda et al. 
(2001)
Thoracotomy 91 1 year Post-thoracotomy pain:
Pain free = 59
Slight pain = 39
Moderate pain = 2
Severe pain = 0
[19]
Nikolajsen 
et al. (2004)
Caesarean section 220 ~1 year Abdominal scar pain = 12.3 [204]
Nikolajsen 
et al. (1997)
Amputation 60 1 year Phantom limb pain = ~70 [15]
Richardson 
et al. (2006)
Amputation 52 6 months Phantom limb pain = 78.8
Stump pain = 51.2
[205]
Jensen et al. 
(1985)
Amputation 58 2 years Phantom limb pain = 59
Stump pain = 21
[17]
Hanley et al. 
(2007)
Amputation 57 2 years Phantom limb pain intensity > 0/10 = 62
Phantom limb pain intensity > 3/10 = 30
Stump pain intensity > 0/10 = 57
Stump pain intensity > 3/10 = 27
[89]
Borly et al. 
(1999)
Open cholecystectomy 80 1 year Pain = 26 [53]
Meyerson 
et al. (2001)
Sternotomy for cardiac 
surgery 
318 1 year Post-sternotomy pain = 28
With pain intensity ≥ 30/100 = 13 
[18]
Nikolajsen 
et al. (2006)
Hip replacement 1048 12–18-month 
prevalence
Chronic hip pain = 28.1
Pain limited activities to a moderate, severe 
or very severe degree = 12.1
[166]
BCT: Breast-conserving surgery; MRM: Modified radical mastectomy.
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it emits a long-lasting, high-frequency burst of activity [36,37]. This 
injury discharge involves a train of impulses produced by freshly 
injured afferent nerve fibers (ruptured myelinated and unmy-
elinated axons) that uses glutamatergic neurotransmission via 
NMDA receptors to sensitize nociceptive pathways in the CNS. 
Injury discharge is under tonic endogenous inhibition by inhibi-
tory interneurons in the spinal cord that use amino acids, such 
as GABA and glycine [38]. The massive glutamatergic activation 
of postsynaptic NMDA receptors on interneurons in the spinal 
dorsal horn, many of which are inhibitory [39], is believed to be 
excitotoxic, leading to their destruction and to disinhibition of 
pain pathways [40–42]. Thus, one very useful preventive measure 
that can be taken when it comes to humans undergoing surgery is 
to avoid intraoperative nerve damage. Obviously, this is not pos-
sible for certain surgeries, such as limb amputation, that involve 
ligation and section of major nerve trunks. However, the practice 
of intentionally transecting nerves for surgical convenience should 
be avoided [24] and doing so will, without doubt, contribute to a 
lower incidence of neuropathic pain [6,43].
Note, however, that many operations do not result in transect-
ing nerve trunks, but in stretching or crushing nerves during 
retraction of tissues when accessing deeper structures, or in cut-
ting skin, fascia, muscles, joints, bony structures and viscera, all 
of which are innervated by sensory fibers. Thus, injuring such 
afferents by stretching the nerve trunk or the tissue it innervates, 
cauterizing or trapping it in a suture or clips, or cutting the tissue 
may be a trigger for increased acute postsurgical pain and pos-
sibly the transition to pain chronicity. In fact, there is a rodent 
model that mimics this type of injury by simply cutting skin and 
underlying muscle without damaging a nerve trunk. The incision 
proposed in the original model was cutting the thigh skin and 
underlying biceps femoris muscle [44]. This injury produced small- 
to medium-sized, pyknotic and hyperchromatic neurons (‘dark 
neurons’) in the upper spinal dorsal horn laminae that process 
nociceptive input. It has been proposed that these changes are pro-
duced by an excitotoxic insult involving NMDA receptor activa-
tion subsequent to injury discharge, and that at least some of these 
neurons are inhibitory interneurons whose functional impairment 
or death contributes to a central state of hyperexcitability that 
underlies neuropathic hyperalgesia and allodynia [44]. A few years 
later, this model was slightly modified by making the incision on 
the plantar surface of the hindpaw of the rodent, cutting through 
skin and muscle, thereby producing heat and mechanical allo-
dynia and hyperalgesia, and guarding behavior that, in the rat, 
lasted 6 days [45]. Subsequent work showed that the heat allodynia 
and spontaneous firing of impulses in C-fibers, innervating the 
skin adjacent to the incision, depended on Vanilloid 1 transient 
receptor potential (Trpv1) receptors, and the allodynia and firing 
of C-fibers were much reduced in Trpv1 gene knockout mice [46]. 
Treating rats that had undergone the plantar postincision pain 
model with the Trpv1 antagonist AMG0347 decreased capsaicin-
induced heat and mechanical hyperalgesia [47]. This model is 
sensitive to opiate treatments, since a small dose of morphine 
affected guarding behavior and responses to noxious abnormal 
heat stimuli [48]. NGF and TNF-a play a role in mediating the 
sensory abnormalities in this model, as they do in other models of 
neuropathic pain following nerve injury [49,50]. However, neither 
gender nor strain (i.e., genetic variation) effects were noted across 
mice of the DBA2/J, C57BL/6J and 129X1/SvJ strains [51]. Since 
the latter two are routine strain platforms for the study of gene 
knockout studies, this confirms that the plantar incision model 
can be used to detect gene effects on the sensory abnormalities 
that characterize it. 
Another variant of the skin and muscle incision model of 
Nachemson and Bennett [44] was adapted for laparotomy, by 
having the incision performed in rats at a subcostal level access-
ing the peritoneal cavity [52]. The surgical procedure produced 
decreased ambulation and rearing by approximately 50% 24 h 
after surgery, which was reversed by morphine (but not the rear-
ing) and ketorolac. There were synergistic effects when the two 
analgesics were coadministered. This model mimics the behav-
ioral aspects of postoperative pain seen clinically, including the 
reported analgesic efficacy and occurrence of side effects found 
with these agents in humans [52].
Psychosocial factors & chronic postsurgical pain
Only recently have researchers begun to examine psychosocial risk 
factors associated with the development of chronic postsurgical pain. 
Several psychosocial predictors of chronic postsurgical pain [23,53,54] 
or chronic postsurgical pain disability [16,55] have been identified, 
including increased preoperative state anxiety [56], an introverted 
personality [53], less catastrophizing, social support and solicitous 
responding in the week after amputation [16,55], higher concurrent 
emotional numbing scores at 6 and 12 months [57], fear of sur-
gery [23], and ‘psychic vulnerability’ [54], a construct similar to neu-
roticism [9]. Solicitous responding includes behaviors on the part of 
significant others that unwittingly positively and/or negatively rein-
force the patient’s pain behaviors thereby increasing their frequency 
of occurrence. For example, in response to a complaint of pain or a 
grimace from the patient when performing a household chore, an 
empathic spouse may tell the patient to rest while she performs the 
task herself. Such solicitous behaviors may, in some instances, have 
the unintended consequence of increasing the frequency of pain 
behaviors and thus contributing to pain-related disability.
Catastrophizing 
Pain catastrophizing is characterized by unrealistic beliefs that the 
current situation will lead to the worst possible pain outcome [58], 
negative thoughts about the future and self [59] and “an exag-
gerated negative ‘mental set’ brought to bear during actual or 
anticipated pain experience” [60]. Pain catastrophizing is a multi-
dimensional construct comprising elements of rumination, mag-
nification and helplessness [60–62]. One of the few consistent find-
ings in the pain literature is that chronic pain patients who do not 
catastrophize fare better than patients who do catastrophize [63]. 
Jensen et al. [55] and Hanley et al. [16] evaluated a biopsychosocial 
model predicting pain interference (disability) and depression in a 
2-year prospective study of 70 patients initially assessed 1 month 
after lower limb amputation. Patients completed a measure of 
PLP intensity and the following psychosocial measures 1 month, 
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6 months [55], 1 year and 2 years [16] after amputation: pain cogni-
tions (catastrophizing, perceived control over pain), pain coping, 
social support, social environment (solicitous responding from a 
significant other), pain interference and depressive symptoms. 
Regression analyses showed that 1-month pain and psychosocial 
measures accounted for a total of 46% of the variance in pain 
interference change scores at the 2-year follow-up. Psychosocial 
measures accounted for 27% of the variance, with catastrophiz-
ing, social support and solicitous responses each accounting for 
a unique and statistically significant portion of the variance. 
Greater social support and less spousal solicitousness (indicating, 
for example, a lesser tendency for spouses to attend to complaints 
of pain and to take over the pain patient’s jobs and duties) and, 
counterintuitively, more frequent catastrophizing at 1 month 
were associated with improvements (greater decreases) in pain 
interference scores 2 years later. In addition, 1-month pain and 
psychosocial measures accounted for a total of 36% of the vari-
ance in change in depressive symptoms at the 2-year follow-up, 
with only catastrophizing contributing a unique and statistically 
significant portion of the variance. 
More frequent catastrophizing predicting better outcome 
appears to be a counterintuitive finding, and may be, in part, 
accounted for by the use-change scores that complicate interpre-
tation. The authors note that those patients who catastrophized 
most at the initial assessment likely had more room for improve-
ment in pain interference and depressive symptoms at the 2-year 
follow-up, suggesting that the findings may be an artifact of using 
difference scores and from a regression to the mean. The authors 
offered an alternative interpretation, suggesting that there may 
be something beneficial about pain catastrophizing early after 
amputation, either because it mobilizes social support resources 
that ultimately assist in recovery and adjustment or because it is 
associated with an acute, adaptive grief reaction that contributes 
to earlier long-term resolution of issues concerning limb loss. 
Alternatively, catastrophizers may seek and receive medical treat-
ments early on that have a lasting effect on impulse generators in 
the amputated nerves and/or the CNS.
In a more recent prospective, longitudinal study, 55 patients 
scheduled to undergo total knee arthroplasty were assessed before 
and at several time points up to 2 years after surgery [64]. In con-
trast to McGill Pain Questionnaire (MPQ) pain scores, which 
decreased over time, catastrophizing scores remained relatively 
constant over the 2-year follow-up period. Regression analyses 
showed that preoperative catastrophizing of a ruminative nature 
significantly predicted MPQ pain ratings 2 years after surgery. It 
remains to be seen whether the relationship between preoperative 
catastrophizing and chronic postsurgical pain after total knee 
arthroplasty is causal or associative. 
Social support & social–environmental factors
The relevance to chronic postsurgical pain of social support in 
general, and solicitous responding in particular, has been estab-
lished in a 2-year prospective study of amputees with PLP [16,55]. 
The relationship between solicitous responding from significant 
others and the patients’ chronic pain intensity and behaviors is 
explained by well established operant conditioning principles. 
The operant model proposes that in offering pain contingent help 
(e.g., taking over household jobs) in response to pain behaviors 
(e.g., guarding, limping) and verbal expressions of pain, well-
intentioned spouses unwittingly negatively reinforce the patient’s 
pain behaviors, leading to an increase in their frequency of occur-
rence [65,66]. As noted previously, greater social support and less 
spousal solicitousness 1 month after amputation were associated 
with improvement in pain interference scores 2 years later.
Chronic postsurgical pain & post-traumatic stress disorder 
Post-traumatic stress disorder (PTSD) typically develops after 
exposure to an event or situation that is perceived to be threat-
ening to the physical or emotional integrity of an individual. 
Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (Text Revision) diagnostic criteria [67] for PTSD cover 
three symptom clusters, including re-experiencing the traumatic 
event (e.g., nightmares and ‘flashbacks’), emotional numbing 
(e.g., feeling detached from others), avoidance of thoughts, feel-
ings and activities associated with the trauma and increased 
arousal (e.g., insomnia, exaggerated startle reflex and hypervigi-
lance). Recent data show that chronic pain and PTSD are highly 
comorbid [68,69].
Salomons et al. presented two case reports of patients who 
developed PTSD following an episode of awareness under 
anesthesia [70]. For both patients, post-traumatic sequelae per-
sisted for years and included pain symptoms that resembled, 
in quality and location, the very pain experienced during sur-
gery. In addition to the similarity to the original pain, these 
pain symptoms were triggered by stimuli associated with the 
traumatic situation, suggesting that they were flashbacks to the 
episode of awareness under anesthesia. Both patients participated 
in individual, trauma focused, cognitive–behavioral therapy with 
successful resolution of the PTSD.
Katz et al. evaluated the relationship between the post-traumatic 
stress symptom (PTSS) emotional numbing and chronic post-
surgical pain disability 6 and 12 months after lateral thoracotomy 
using a prospective, longitudinal design [57]. A total of 54 patients 
who were scheduled to undergo posterolateral thoracotomy for 
intrathoracic malignancies were recruited 1 week before surgery 
and completed validated questionnaires assessing pain disability 
and PTSS. Pain intensity and total morphine consumption were 
recorded 24 and 48 h after surgery; 6 and 12 months after surgery 
patients were telephoned to determine chronic postsurgical pain 
incidence, pain disability and PTSS. The incidence of chronic 
post-thoracotomy pain was 68.1 and 61.1% at the 6- and 12-month 
follow-ups, respectively. Multiple regression analyses showed that 
neither preoperative factors nor acute movement-evoked post-
operative pain predicted 6- or 12-month pain disability. However, 
concurrent pain intensity and emotional numbing, but not avoid-
ance symptoms, made unique, significant contributions to the 
explanation of pain disability at each follow-up (total R2 = 76.3 and 
63.9% at 6 and 12 months, respectively). Over time, the relative 
contribution of pain intensity decreased, while that of emotional 
numbing increased, indicating a progressive decoupling of pain 
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intensity and disability and a concomitant strengthening of the 
link between emotional numbing and disability. This suggested 
that pain may serve as a traumatic stressor that causes increased 
emotional numbing. The source of the emotional numbing is 
not known; it may arise from living with pain, which serves as a 
reminder of the cancer or living with a diagnosis of cancer, as well 
as the threat of and/or a recurrence of cancer. It is also possible 
that the emotional numbing is, in part, due to a previous unrelated 
traumatic event. Further research is needed to determine the role 
(if any) of the endogenous opioid system in mediating this effect. 
It is interesting to add in this context that there is a growing body 
of literature indicating that living with chronic pain is associated 
with structural changes (usually thinning) of the cortex in parts 
of the brain typically associated with aversive-affective processing 
of pain in the several chronic pain syndromes [71–75]. 
Kleiman et al. provided preliminary evidence for a construct 
termed sensitivity to pain traumatization (SPT), which describes 
the anxiety-related psychological and emotional reactions, as well as 
behavioral responses to pain that resemble symptoms of PTSD [76]. 
They evaluated the relationships among commonly used pain-
related measures of anxiety and fear in 372 patients approximately 
1 week prior to major surgery. Exploratory factor ana lysis (unro-
tated) of the combined scale items (n = 79) supported a two-factor 
solution accounting for 30 and 9.9% of the variance, respectively, 
and consisting of 75 items. Since the first factor included all but 
one item in the second factor, a one-factor solution better approxi-
mated the simple structure. A rotated (Varimax) solution suggested 
the existence of 11 small independent factors (each accounting for 
between 2 and 11% of the variance) comprising the same 74 items 
as in factor one of the unrotated solution, and accounting for 
57.6% of the shared variance. The pattern of findings suggested 
that several lower order factors loaded on a single higher order 
factor, which they called SPT. Evidence for an overlap between 
SPT and PTSD symptoms involved clusters of lower order SPT 
factors describing intrusive thoughts, behavioral avoidance and 
hyperarousal. Importantly, SPT showed a strong and significantly 
positive correlation (r = 0.52) with the total score on the PTSD 
Checklist – Civilian Version suggesting good preliminary construct 
validity for SPT.
Taken together, the results of these studies [57,70,76] indicate that 
PTSSs are associated with concurrent [57,76] and subsequent [57,70] 
pain and pain disability, months to years later, but the nature of 
the mechanisms underlying these relationships remain to be deter-
mined. One possible reason for the high comorbidity of PTSD and 
chronic pain may be the substantial symptom overlap common to 
both disorders, including: anxiety and hyperarousal, attentional 
biases, avoidant behaviors, emotional lability, and elevated somatic 
focus [68]. The overlap in symptoms suggests the two disorders may 
be mutually maintaining [68,77]. The idea of mutual maintenance 
may be linked to a common or shared underlying psychological 
vulnerability that may depend on shared genetic determinants and 
which places at-risk individuals at greater risk of developing one 
or both disorders. Anxiety sensitivity has been identified as one 
of the trait vulnerability factors that predispose individuals to the 
development of chronic pain, PTSD or both [68]. 
The intractability of the two disorders is not surprising when 
viewed in the context of mutual maintenance and shared vul-
nerability models. This underscores the importance of screening 
for both disorders when either one is present. This may be espe-
cially relevant in patients scheduled for major surgery given that 
diagnosis and surgery are highly stressful events and that many 
individuals scheduled for surgery also have chronic pain. 
From a treatment perspective, there is very little published on 
comorbid PTSD and chronic pain [78] and nothing published on 
patients scheduled for surgery. There is some evidence that a cogni-
tive–behavioral perspective that addresses both disorders is essential; 
otherwise, treatment of one (and not the other) would be expected 
to lead to partial recovery or, if complete recovery occurred in one 
domain, recovery might be transient [68,70,78]. The decoupling of 
pain and PTSD symptoms with time would argue for the need of an 
early initiation of treatment. However, until we know more about the 
source and nature of the traumatic stressors that patients experienced, 
it may be premature to make treatment recommendations.
Patient-related factors associated with chronic 
postsurgical pain
One of the most consistent patient-related factors found to be 
associated with the development of acute and chronic postsurgical 
pain is concurrent or past pain [6,9,79,80]. This appears to be true 
across surgery types and regardless of time frame. The presence 
of preoperative pain, or its intensity or duration, is a risk factor 
for the development of severe early acute postoperative pain [81], 
acute pain days [13,17,82–84] and weeks [85] after surgery, as well 
as long-term postsurgical pain [17,24,57,64,82,85–90]. Not only does 
preoperative pain predict later pain, severity of acute postopera-
tive pain in the days and weeks after surgery predicts pain after 
discharge [85,91] and is also a risk factor for the development of 
chronic postsurgical pain [10,89,92–100]. 
No other patient factor is as consistently related to the develop-
ment of future pain problems as is pain itself. Female gender [81,85] 
and younger age [81,85,98] predict chronic postsurgical pain, but not 
with the consistency or magnitude with which pain predicts pain. 
What must be determined, however, is the aspect(s) of pain that 
is predictive. There are several possibilities for why pain predicts 
pain, including those that propose a causal or associative role. The 
following factors are not mutually exclusive:
• Intraoperative nerve damage and the injury discharge that it 
causes [36–38]; 
• Sensitization of nociceptors in the surgical field [93]; 
• Early postoperative ectopic activity in the regenerating sprouts of 
injured primary afferents and in somata of these fibers in dorsal 
root ganglia associated with the injured nerves [101], and even in 
somata of intact neurons in dorsal root ganglia neighboring those 
associated with injured nerves [102]; 
• Collateral sprouting from intact nociceptive Ad afferents that 
neighbor the field innervated by injured afferents [94,103];
• Central sensitization induced by the surgery and maintained 
by peripheral input [40,104–106];
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• Structural changes in the CNS induced by perioperative noci-
ceptive activity (e.g., disappearance of antinociceptive inhibi-
tory interneurons in the spinal dorsal horn [41,42] centralization 
of pain and somatosensory pain ‘memories’ [105,107,108]); 
• Heretofore unidentified pain genes that confer increased risk 
of developing intense acute pain and chronic postsurgical 
pain [109–114];
• Consistent response bias over time. Some individuals have a 
tendency to report more intense pain than other individuals [79]. 
Thus, they would report intense pain immediately after surgery 
as well as in the long term. Excluding this possibility is impor-
tant for establishing other plausible mechanisms for the pain 
(e.g., see [94]);
• Psychological and emotional factors, including emotional 
numbing [57] and catastrophizing [16,55,64]; 
• Social from environmental factors, such as solicitous responding 
from significant others [16,55] and social support [16];
• Publication bias in which findings of a significant relationship 
between pain before and after surgery are published whereas 
negative findings do not make it into print.
Genetics of chronic postsurgical pain 
The genetics of pain is a very young research field (for recent 
reviews see [112,113]). Therefore, it should come as no surprise that, 
as of yet, there are no published reports about genes predisposing 
humans for the transition of acute pain after surgery to chronic 
postsurgical pain. There are only a few reports that have identi-
fied polymorphisms in human genes associated with chronic 
pain. These include polymorphisms in the following genes: 
5-HTTLPR (the gene encoding the serotonin transporter) that 
were found to associate significantly with levels of migraine [115], 
burning mouth syndrome [116], irritable bowel syndrome [117] and 
fibromyalgia [118]; IL1B (encoding IL-1b) plays a role in burning 
mouth syndrome [116]; IL1RN (encoding IL-1 receptor antago-
nist) and MC1R (encoding the melanocortin-1 receptor) in vul-
vodynia [119]; IL23R (which encodes a subunit of the receptor for 
IL-23) in Crohn’s disease [120]; GCH1 (encoding GTP cyclohy-
drolase, an enzyme catalyzing tetrahydrobiopterin, BH4, an 
essential cofactor for catecholamine, serotonin and nitric oxide 
production) has been implicated in persistent radiculopathic pain 
following surgical diskectomy (note that the sought association 
in this study was not with pain postsurgery but with surgical alle-
viation of an existing chronic lumbar root pain that was caused 
by disk herniation) [121]; COMT (encoding catechol-O-methyl 
transferase, the enzyme that inactivates dopamine, epinephrine 
and norepinephrine in the nervous system) has been implicated 
in a number of chronic pain entities (for review see [122]); and 
polymorphisms in CACNA1, ATP1A2, MTHFR, SCN1A and 
the female hormone genes ESR1, ESR2 and FSHR have been 
implicated in migraines (for review see [123]). Note, however, that 
in many of these studies it has not been established whether the 
identified genetic determinants were associated with chronic pain 
indirectly, by producing a disease that carries a morbidity for 
chronic pain, or directly, by producing and maintaining chronic 
pain once having the disease. 
Pain genetic studies that are relevant to chronic postsurgical 
pain in rodent models have yielded the following results. Note 
that these models were not explicitly developed to model chronic 
postsurgical pain per se, yet used surgical approaches to injure 
peripheral nerves, spinal nerves, dorsal roots and the spinal 
cord [26–33,124]. Some of these models were used to determine 
the level of heritability for spontaneous and stimulus-induced 
neuropathic pain [114] in evaluating genetic differences across lines 
and strains of mice and rats in traits relevant to chronic postsurgi-
cal pain in humans [110,111,125–130], and the effect of genetic and 
environmental interactions on chronic postsurgical pain-related 
behaviors in these models [131–133]. These models were also used 
to map chromosomal regions (termed quantitative trait loci) that 
harbor chronic postsurgical pain-related genes [114,125,131,134,135]. 
These intervals were mapped using sets of recombinant inbred 
lines that were produced by repeatedly breeding two inbred paren-
tal lines [125], or by genotyping F2 offspring of inbred lines that 
contrast on the chronic postsurgical pain strain under study [134]. 
Using gene-expression and proteomic methods, hundreds of genes 
and proteins were identified in dorsal root ganglia and spinal cord 
(but none in supraspinal structures as of yet) of mice and rats in 
chronic postsurgical pain-related models [136–143]. Furthermore, 
manipulations of individual genes by overexpression or deletion 
(in transgenic ‘knockout’ experiments), or by shutting off expres-
sion using siRNA or antisense oligodeoxynucleotide injections, 
have identified over 240 rodent genes that have some demon-
strated role in various acute and chronic pain models, some of 
which are relevant to chronic postsurgical pain. The information 
about these genes and the models in which they were studied is 
accessible on the internet [301]. 
Phenomics of chronic postsurgical pain
A gene for chronic postsurgical pain is identified when evidence is 
presented of a statistically significant ‘association’ between a pain 
trait characterizing chronic postsurgical pain and a genetic marker, 
usually a single nucleotide polymorphism in or near these genes. 
Thus, discovering such genes critically depends on the pain traits 
collected from participants in a given cohort. There is currently no 
consensus over what these pain traits should be; moreover, ‘pain 
phenomics’, the research field that constructs questionnaires and 
other tools to collect clinically-relevant pheno typic pain data for 
genetic studies, has not been born as of yet. Consequently, phe-
nomic questionnaires for chronic pain are currently unavailable 
but critically important to the identification of genes for chronic 
postsurgical pain. Chronic postsurgical pain, like other chronic 
pain syndromes, is multifaceted, characterized by multiple sen-
sory–discriminative, affective–emotive and cognitive–evalua-
tive variables. In order to identify genes for these dimensions/
aspects and solve clinical problems of chronic post surgical pain 
by addressing the neural structures and networks that bring 
them about, one should faithfully characterize each patient in as 
much detail as is practical. It is not enough to collect from the 
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participants a categorical answer as to whether or not he/she has 
chronic postsurgical pain, and it is also not enough to limit the 
description of chronic postsurgical pain to the intensity of pain on 
a 0–10 visual analog scale. This is because there may very well be 
different genes controlling the interindividual variability in pain 
intensity of a typical pain episode, different genes for the frequency 
of such episodes, other genes for the amount of suffering the pain 
causes, additional genes for the type of the pain (e.g., ‘burning’ 
vs ‘electrical shock-like’), yet different ones for the spread of pain 
beyond the surgical field where nerves were injured and so on. 
Therefore, if we are to provide a comprehensive solution to chronic 
postsurgical pain based on genetics, we must develop tools and 
questionnaires to collect from every participant in a genetic study 
a broad array of phenotypes (i.e., quantifiable pain traits). 
Expected gains for chronic postsurgical pain medicine in 
the postgenomic era
It is expected that a replicated genome-wide association study 
of chronic postsurgical pain, if powered statistically to detect 
genetic variations of small effects, followed by gene validation 
experiments, will discover most genetic variations that affect 
the transition to pain chronicity [113,144,145]. This knowledge will 
be translated to the development of novel diagnostic kits that 
assess the risk an individual carries for developing chronic pain 
(if undergoing a surgery that carries significant morbidity for 
chronic postsurgical pain). Similar kits are expected to provide 
prognostic predictions that would enable caregivers to ‘tailor’ the 
best treatment choices an individual is expected to benefit from, 
based on his/her ‘genetic fingerprints’. These kits could also be 
used to better select subjects for clinical trials, thereby minimizing 
costs and shortening drug development times. New compounds 
would be developed that provide effective pre-, intra- and post-
operative care, thereby preventing the outbreak of chronic post-
surgical pain. Tagging the product of such genes with antibodies 
and carrying out immunohistological studies in animal models 
of chronic postsurgical pain could uncover new pain mechanisms 
and identify neuronal and/or glial cell types expressing chronic 
postsurgical pain genes, and their networks, some of which 
are currently unknown to us. Better rodent models that carry 
chronic postsurgical pain genes, relevant to human pain, could 
be developed and used as a platform to test the efficacy of novel 
drugs for chronic postsurgical pain. Finally, gene therapy would 
make it possible to patch ‘bad’ gene variants that carry the risk 
for chronic postsurgical pain. Judging by the rapid advancements 
in the Genome Project, this futuristic scenario may become a 
reality in our lifetime. 
Preventive analgesia
As depicted in Figure 1, it is important to ascertain the precise 
mechanisms that underlie the relationship between pain at time 
one (e.g., preoperative pain or acute postoperative pain) and pain 
at time two (e.g., 1 year after surgery). The idea that pain is in 
some way etched into the CNS [108,146,147] has been at the heart 
of efforts to halt the transition to chronicity by blocking noxious 
perioperative impulses from reaching the CNS using a pre-emptive 
or preventive pharmacological approach. However, if the relation-
ship between acute postoperative pain and chronic pain is merely 
associative, and both are caused by one or more factors that them-
selves are inter-related, then no type or amount of blocking will 
prevent the development of chronic postsurgical pain.
Studies in a rodent model of PLP indicated that blocking 
afferent input from the surgical field at the time of nerve injury 
and shortly thereafter prevents chronic neuropathic pain-related 
behavior, while artificially prolonging it, especially in C-fibers, 
increases the chronic pain behavior [36,37,38,129,148–150]. This line 
of basic science research continues to introduce novel compounds 
(e.g., ralfinamide [150]) that show positive pre-emptive effects in 
rodent models of neuropathic pain and which could be tested 
as pre-emtpive analgesics in humans. These findings have taken 
a long time to impact clinical practice and, as such, the man-
agement of acute postoperative pain has been dominated by an 
outdated concept of pain. Pain was viewed as the end product 
of a passive system that faithfully transmits a peripheral pain 
signal from nociceptors to a pain center in the brain. This view 
has resulted in a strategy for managing postoperative pain that is 
inadequate, in part because it treats the patient only after the pain 
is well established. Patients arrive in the postanesthetic care unit 
(recovery room) after surgery, often in extreme pain, where they 
receive multiple doses of analgesics in a short period of time in an 
effort to bring the pain down to a tolerable level [151,152]. However, 
basic science and clinical data show that brief, noxious inputs or 
frank injury that activates A- and mainly C-fibers (e.g., cutting 
skin, muscle or nerve fibers) induce long-lasting changes in cen-
tral neural function that persist well after the offending stimulus 
has been removed or the injury has healed [40–42,44,104–107]. This 
view of pain, involving a dynamic relationship between periph-
eral and central mechanisms, is inconsistent with the archaic 
notion that pain results from transmission of impulses along a 
straight through, feed-forward pathway from a site of injury to 
the brain [153]. 
The practice of treating pain only after it has become well 
entrenched is slowly being replaced by a preventive approach that 
aims to block the transmission of the primary afferent injury 
discharge, the inflammatory response, and ensuing ectopic activ-
ity [154–157]. The intent behind this approach is not simply that it 
reduces nociception and stress during surgery – although these 
are also worthwhile objectives. The idea that acute postoperative 
pain might be intensified by a state of central neural hyperexcit-
ability induced by surgery can be traced to Crile [158] and later to 
Wall [159], who suggested that ‘pre-emptive preoperative analgesia’ 
would block the induction of central neural sensitization brought 
about by incision and thus reduce acute postoperative pain inten-
sity. Since its introduction, this concept has been refined, based in 
part on confirmatory and contradictory clinical evidence, devel-
opments in basic science and critical thought. The suggestion 
that surgical incision triggers central sensitization [159] has been 
expanded to include the sensitizing effects of preoperative noxious 
inputs and pain, other noxious intraoperative stimuli, as well as 
perioperative peripheral and central inflammatory mediators and 
ectopic neural activity [160]. 
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Transition from acute to chronic postsurgical pain
The perioperative period can be divided 
into three distinct phases: pre-, intra- and 
post-operative. Specific factors within these 
phases contribute to the development of 
acute postoperative pain. These factors 
include: preoperative noxious inputs and 
pain; A- and C-fiber injury barrage result-
ing from the cutting of skin, muscle, nerve 
and bone, or wound retraction; and post-
operative peripheral nociceptive input and 
input in low-threshold afferents, includ-
ing that arising from the inflammatory 
response and ectopic neural activity in the 
case of nerve injury. Each of these factors 
can contribute to peripheral and central 
sensitization and each, therefore, can be 
targeted using a preventive approach. We 
propose that the relative contribution of 
these factors to acute postoperative pain is 
dependent on the surgical procedure, extent 
and nature of tissue damage, duration of 
surgery, timing of treatments relative to 
incision, pharmacokinetics of the agent(s) 
used preoperatively, presence or absence 
of additional analgesia intraoperatively, 
nature of postoperative analgesia and many 
other variables, including the genetic back-
ground that contributes a predisposition to 
be affected by any one of the parameters 
mentioned earlier. Minimizing the nega-
tive impact of as many as possible of these 
factors across the three perioperative phases 
will increase the likelihood of preventing 
the induction and maintenance of periph-
eral and central sensitization. Preventing 
sensitization will reduce pain and analgesic 
requirements [160].
In contrast to pre-emptive analgesia, 
which requires two groups of patients to 
receive identical treatment before or after 
the same type of incision or surgery [161], the 
focus of preventive analgesia is not on the relative timing of anal-
gesic or anesthetic interventions, but on attenuating the impact 
of the peripheral nociceptive barrage associated with noxious 
preoperative, intraoperative and/or postoperative events/stimuli. 
The rationale for preventive analgesia is to capitalize on the com-
bined effects of several analgesic agents, administered across the 
preoperative, intraoperative and postoperative periods, in reduc-
ing peripheral and central sensitization [160]. Therapeutic benefits 
associated with multimodal regimens include improved efficacy, 
lower doses and fewer adverse effects [162]. 
Preventive analgesia is demonstrated when postoperative pain 
and/or analgesic use are reduced beyond the clinical duration of 
action of the target agent, which has been defined as more than 
5.5 half-lifes of the target agent [160,163]. This requirement ensures 
that the observed effects are not simply analgesic effects. A recent 
review of the preventive analgesia literature indicates that, across 
a variety of classes of agents, preventive analgesia reduces pain, 
analgesic consumption or both at a point in time that exceeds 
5.5 half-lifes of the target agent [160]. Although the evidence favors 
a preventive approach, relatively few studies have been designed 
to examine the possibility that chronic postsurgical pain can be 
prevented or attenuated, as reviewed later.
Postamputation PLP
A series of studies, beginning with the promising results of the 
nonrandomized study by Bach et al. [164], have examined the 
long-term benefits of perioperative epidural analgesia in reducing 
the incidence and intensity of PLP after limb amputation [165]. 
Figure 1. Causal (top) and associative (bottom) hypotheses predicting the 
prevention and nonprevention of chronic postsurgical pain by pharmacologic 
blockade at various times throughout the perioperative period. Top: transition to 
chronicity (A,B) may be prevented by pharmacological blockade of preoperative pain (C) 
and/or acute postoperative pain (D) assuming preoperative or acute postoperative pain 
are the causes of chronic postsurgcial pain. Bottom: transition to chronicity will not be 
prevented if pains are merely associated and caused by one or more inter-related factors.  
post-op: Postoperation.
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The initial promise, however, has not materialized. In what 
is perhaps the most methodologically sound study conducted 
on the topic to date, Nikolajsen et al. evaluated the long-term 
effects on phantom limb and stump pain of continuous epidural 
morphine and bupivacaine administered 18 h before, during 
and for approximately 1 week after lower limb amputation [166]. 
The control group received epidural saline before and through-
out the surgical procedure followed by epidural morphine and 
bupivacaine postoperatively. There were no significant differ-
ences between the groups in pain incidence, intensity or opi-
oid consumption at any time up to 12 months after surgery. 
Subsequent randomized, controlled studies using perioperative 
epidural bupivacaine and diamorphine [167], intrathecal bupi-
vacaine and ketamine [168], intravenous ketamine for 3 days [169], 
epidural bupivacaine and ketamine for up to 3 days [168] have 
failed to find a significant long-term reduction in PLP inci-
dence or intensity compared with placebo control conditions. 
Moreover, only one [170] of the three randomized, double-blind 
studies [170–172] conducted to evaluate the efficacy of oral gabap-
entin on already established PLP has shown a superiority of 
gabapentin over a placebo control condition. 
The one recent positive study by Schley et al. compared two 
groups that underwent unilateral amputation ranging from 
removal of one finger to the entire forearm [173]. All amputees 
received postoperative analgesia by continuous brachial plexus 
anesthesia (ropivacaine 0.375% 5 ml/h) for 7 days. Thereafter, all 
participants could receive additional boli of ropivacaine 0.375% 
upon request. The main variable of difference between the groups 
was that for 4 weeks postamputation, one group received a daily 
dose of the NMDA receptor blocker memantine (20–30 mg) and 
the other group received placebo. During the first week post-
amputation, the memantine-treated group needed significantly 
fewer local anesthetic blocks of the brachial plexus to relieve their 
pain. Moreover, at 4 weeks and 6 months after surgery, but not at 
12 months, the memantine-treated group had significantly lower 
rates of PLP, and those with PLP reported lower pain intensity 
compared with the placebo group.
Several related issues require further study with regard to 
prevention of postamputation PLP:
It is important to distinguish between the effects of pre-
amputation pain location, duration, frequency and intensity [108], 
and those of the surgical procedure (i.e., cutting of skin, muscle, 
bone, and ligation and transection of major nerve trunks) on 
the development of chronic PLP and stump pain [108]. To date, 
studies have not separately evaluated the nature, quality and 
intensity of preamputation pain versus acute postamputation 
pain. Other, more recent studies in nonamputee populations, 
have examined this issue as it pertains to the development of 
acute, as opposed to chronic, postsurgical pain. The data suggest 
that in the presence of presurgical pain, preoperative administra-
tion of analgesics does not lead to the anticipated lessening of 
postoperative pain or analgesic consumption, perhaps because 
central sensitization has already been established and the treat-
ment could not reverse it. Postoperative pain and analgesic con-
sumption were significantly reduced by pre- and intra-operative 
epidural morphine, but not saline, for patients who did not report 
presurgical pain [174]. However, among patients with presurgical 
pain, pre- and intra-operative epidural morphine was no more 
effective than saline [174]. This raises the important issue of what 
effect blocking preoperative pain would have on the intensity of 
acute postoperative pain. A recent study of patients undergoing 
total hip arthroplasty showed that relief of preoperative pain by 
epidural ropivacaine for at least 12 h before surgery, followed by 
intra operative epidural ropivacaine, reduced patient-controlled 
epidural anesthesia ropivacaine consumption 48 h after surgery 
compared with preoperative epidural saline and intraoperative 
epidural ropivacaine [175]. Based on these interesting and con-
troversial findings, future studies should report on the presence 
(and duration) or absence of presurgical pain. 
An important factor that has not received much attention is 
the distinction between preoperative pain related to the surgical 
procedure (i.e., in the anatomical region of the surgery, such as 
preoperative pain in the limb to be amputated) and pain that 
is unrelated to the surgical procedure (e.g., chronic lower back 
pain in a patient scheduled for posterolateral thoracotomy). A 
recent study of patients following radical prostatectomy found 
that patients were significantly at risk of developing chronic post-
surgical pain whether or not the preoperative pain was related to 
the surgical site [90]. This distinction is important, not only to 
PLP after limb amputation, but to all surgeries, since these two 
situations may implicate different mechanism(s) underlying the 
development of chronic postsurgical pain. 
A coexisting disease that affects peripheral nerve function may 
have contributed to the general lack of significant findings [176]. 
Likewise, such disease could have a deleterious effect on the neu-
roprotective capacity of the CNS to resist the excitotoxic impact 
of injury discharge. The vast majority of negative studies have 
recruited patients with diabetes and/or peripheral vascular dis-
ease, in contrast to the positive results found by Schley et al., who 
studied individuals with acute trauma of the upper extremity 
requiring amputation [173].
Finally, further study is needed to improve the effectiveness of 
the perioperative blockade by using local anesthesia of peripheral 
nerves plus intrathecal analgesia. To date, the vast majority of 
negative studies have used epidural analgesia, which may not pro-
vide a sufficiently dense afferent blockade [177] to prevent central 
sensitization and rostral transmission of afferent input. Even a 
clinically effective blockade with intrathecal bupivacaine does not 
completely block nociceptive impulses from reaching the brain 
[178], suggesting that central sensitization might take place even 
with subclinical nociceptive inputs. 
Postmastectomy pain
Recent evidence from well-controlled studies indicates that 
gabapentin, which binds to the a-2-d subunit of the calcium 
channel (Ca
v
a
2
-d [179]), provides profound pain relief and opi-
oid-sparing effects in the acute postoperative setting [180]. Two 
studies have focused on prevention of chronic postsurgical pain 
following breast surgery. Fassoulaki et al. randomized 50 patients 
undergoing breast cancer surgery to one of two groups using a 
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triple-dummy, double-blind design [181]. Patients in the multi-
modal treatment group received gabapentin (400 mg q6 h) start-
ing the evening before surgery, transdermal eutectic mixture of 
local anesthetics (EMLA cream) beginning the day of surgery, and 
intraoperative ropivacaine irrigation of the brachial plexus and 
several intercostal spaces. Patients in the control group received 
placebos in place of the three active agents. After surgery, patients 
continued to receive gabapentin (400 mg) or placebo every 6 h for 
8 days in addition to transdermal eutetic mixtures of local anes-
thetic cream or placebo cream daily for 3 days. At 3, but not 6, 
months after surgery, patients in the multimodal treatment group 
had a significantly lower incidence of axilla pain (14 vs 45%), arm 
pain (23 vs 59%) and analgesic use (0 vs 23%) compared with 
the placebo control patients.
These results contrast with an earlier randomized controlled 
trial by the same group using the same patient population [182]. 
Patients scheduled for breast surgery for cancer were randomly 
assigned to receive gabapentin (200 mg), mexiletine (400 mg) or 
placebo capsules three-times daily beginning the evening before 
surgery and continuing for 10 days after surgery. Although gaba-
pentin proved to be significantly more effective than mexiletine 
or placebo in reducing acute movement-evoked pain intensity 
in the first 5 days after surgery, the 3-month follow-up failed to 
demonstrate a difference in the incidence or intensity of chronic 
pain. However, the incidence of burning pain was significantly 
lower in the two treatment groups compared with the placebo 
control group [182]. The failure to find a significant reduction in 
pain incidence or intensity at the follow-up may have been owing 
to an insufficient dose of gabapentin. 
Iohom et al. compared the efficacy of a comprehensive, preven-
tive multimodal analgesic regimen to a standard treatment in a 
randomized, nonblinded trial of 29 women undergoing surgery 
for breast cancer (mastectomy or breast tumor resection with axil-
lary node clearance) [100]. Patients in the standard treatment group 
(Group S) received intramuscular morphine (0.1 mg/kg every 
4 h), diclofenac suppositories (100 mg every 12 h) and dextro-
propoxyphene hydrochloride 32.5 mg plus oral acetaminophen 
650 mg every 6 h for 48 h. Beginning 12 h before surgery, patients 
in Group N received intravenous parecoxib (a COX-2 inhibitor) 
40 mg every 12 h followed by oral celecoxib (a COX-2 inhibitor) 
200 mg until day 5 after surgery. In addition, before surgery, a 
paravertebral catheter was inserted and a continuous block estab-
lished for up to 48 h after surgery with bupivacaine 0.25% (10 ml 
12 hourly). Finally, patients in Group N also received oral aceta-
minophen 1 g every 6 h for 48 h. All patients received a general 
anesthetic for surgery. Pain intensity after movement was signifi-
cantly lower in Group S compared with Group N across the 48-h 
study period. A telephone follow-up 2–3 months later, conducted 
by a blinded interviewer, showed a significantly lower incidence 
(and intensity) of chronic postoperative breast surgery pain in 
Group N (0%) than Group S (85%). While it is not possible to 
attribute the long-term prevention of pain specifically to COX-2 
inhibition, these results do suggest that parecoxib and celecoxib 
contributed to the reduced incidence of chronic pain, consist-
ent with evidence and predictions from the basic sciences [183]. 
Notwithstanding these positive effects, there have been serious 
concerns raised regarding the potential increased risk of cardio-
vascular thrombotic and myocardial events associated with the 
administration of COX-2 inhibitors [184–186] and, more generally, 
with nonselective NSAIDs [184]. 
Postradical prostatectomy pain
Gottschalk et al. conducted a randomized, double-blind study 
of 100 men undergoing radical retropubic prostatectomy [187]. 
Patients were assigned to one of the three groups to receive either 
preoperative epidural bupivacaine, epidural fentanyl or epidural 
saline followed by postoperative patient-controlled epidural anal-
gesia with morphine and bupivacaine for all three groups. Acute 
pain intensity while in hospital was significantly lower in the two 
groups treated before incision compared with the saline control 
condition. Patients were followed up by telephone interview 3.5, 
5.5 and 9.5 weeks after surgery. Activity scores 3.5, but not 5.5 
or 9.5, weeks after surgery, were significantly higher than in the 
groups that received the epidural agents before and during sur-
gery. The incidence of pain at 9.5, but not at 3.5 or 5.5, weeks 
after surgery was significantly lower in the groups that received 
the epidural agents before and during surgery compared with 
the control group. The authors concluded that the intraoperative 
administration of epidural fentanyl or bupivacaine significantly 
reduces the intensity of acute postoperative pain, pain incidence 
9.5 weeks after surgery and is associated with higher activity 
levels postdischarge.
Katz et al. evaluated the short- and long-term effects of pre-
operative or postincisional intravenous fentanyl plus low-dose 
intra venous ketamine versus a standard treatment receiving 
intravenous fentanyl but not ketamine on postoperative pain and 
analgesic use in men undergoing radical prostatectomy under 
general anesthesia [188]. Pain scores and von Frey pain thresholds 
did not differ significantly among groups at any point in time 
during the first 3 days after surgery. Although day 3 cumulative 
patient-controlled analgesia (PCA) did not differ significantly 
among groups, on the third day after surgery the hourly rate of 
morphine consumption was significantly lower in the pretreated 
group compared with the two other groups. Follow-ups at 2 weeks 
and 6 months did not reveal significant group differences in pain 
incidence, intensity, disability or mental health. The addition of 
low-dose intravenous ketamine to a standard general anesthetic 
did not result in a clinically meaningful reduction in short-term 
pain or morphine consumption. Given the ineffective interven-
tion, it is not surprising that there were no differences in the 
longer term.
Post-thoracotomy pain
Three studies have attempted to prevent the incidence and/or 
intensity of chronic pain after posterolateral thoracotomy with 
preoperative thoracic epidural analgesia [95,189,190]. Obata et al. 
compared the pre-emptive effects of administering a 72-h epi-
dural infusion of a local anesthetic, mepivacaine, beginning 
before incision versus after completion of surgery in 70 patients 
scheduled to undergo thoracotomy [189]. Follow-up at 3 and 
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6 months showed a significant reduction in the incidence of 
chronic post-thoracotomy pain in the group of patients that 
received the epidural before surgery. These results were not con-
firmed by Ochroch et al. who randomly assigned 175 patients to 
receive thoracic epidural bupivacaine and fentanyl before inci-
sion or after rib approximation [190]. The incidence of chronic 
post-thoracotomy pain at 48 weeks did not differ significantly 
between the groups treated before versus after incision. Similarly, 
Senturk et al. randomized 69 patients scheduled to undergo tho-
racotomy to one of three groups: preoperative thoracic epidural 
bupivacaine and morphine followed by postoperative epidural 
PCA, postoperative epidural PCA with bupivacaine and mor-
phine or postoperative intravenous PCA with morphine [95]. In 
contrast to the results of Obata et al., there were no significant 
differences 6 months after surgery between the two epidural 
groups, but both showed a significantly lower incidence and 
intensity of chronic post-thoracotomy pain than the intrave-
nous PCA group [189]. A more recent report examined the effi-
cacy of gabapentin in reducing established post-thoracotomy 
pain [191] based on preliminary findings from a case series of 
patients with severe pain at least 4 weeks after thoracic surgery 
or trauma [192]. Patients were recruited into the trial if they 
had moderate-to-severe chronic post-thoracotomy pain (>5 on 
a 10 cm Visual Analogue Scale [VAS] and >12 on the Leeds 
Assessment of Neuropathic Symptoms and Signs [LANSS]) of 
at least 3 months duration that had proved refractory to ear-
lier treatment and were assigned to receive either gabapentin or 
sodium naproxen (a nonselective NSAID) [191]. At the end of the 
60-day treatment period, the percentage 
of patients that still had severe pain was 
reduced significantly in the gabapentin 
group (15%) compared with the naproxen 
group (~85%). Although these two stud-
ies were not randomized or blinded, they 
point to the next logical step of adminis-
tering gabapentin before surgery and for 
several months following surgery in an 
attempt to prevent the development of 
chronic post-thoracotomy pain. 
Chronic pain after iliac crest bone 
graft harvest
Iliac bone graft harvest for spinal fusion 
results in significant morbidity, including 
functional impairment, as well as severe 
pain at the harvest site in approximately 
3% of patients [193]. Two small scale, ran-
domized, controlled, double-blind studies 
have attempted to prevent chronic bone 
graft harvest site pain with multiple injec-
tions of bupivacaine or bupivacaine and 
morphine into the harvest site beginning 
10 min after the start of surgery [194] and 
a 48-h continuous infusion of bupivacaine 
into the harvest site beginning at the time 
of wound closure after procurement of the graft [195]. Both studies 
found a significant reduction in acute postoperative harvest-site 
pain and analgesic consumption, indicating that the interven-
tions were efficacious. By 12 weeks after surgery the incidence of 
harvest-site pain was significantly lower in the bupivacaine plus 
morphine treated patients (none out of 15) than the saline control 
group (five out of 15) [196]. In the other study, a 4-year follow-up 
showed that chronic pain was not present in any of the nine bupi-
vacaine-treated patients and was present in seven out of the ten 
saline controls [195]. Replication of these results with a larger sam-
ple size is required. These studies suggest that preventive analgesia 
can be achieved even when the analgesic intervention is started 
after incision and bone graft harvest (i.e., in the context of an 
unchecked peripheral nociceptive injury barrage during surgery).
Long-term pain after major  
abdominal–gynecological surgery
Katz et al. evaluated the short- and long-term preventive effect of 
perioperative administration of intravenous alfentanil for women 
scheduled for abdominal hysterectomy performed under general 
anesthesia [196]. In total, 45 patients were randomly assigned to 
one of three groups in a double-blinded manner to receive no 
alfentanil, low-dose alfentanil (30 µg/kg at induction followed by 
intraoperative bolus doses of alfentanil 10–20 µg) or high-dose 
alfentanil (100 µg/kg at induction followed by an intra operative 
infusion of alfentanil 1–2 µg/kg/min) before and during sur-
gery. The results showed that, although a composite measure of 
pain and morphine consumption was significantly lower in the 
Figure 2. Illustration of the study by Fassoulaki et al. [181] examining the 
preventive effect of gabapentin (a Cava2-d ligand) in women undergoing breast 
cancer surgery. 
EMLA: Eutectic mixture of local anesthetics; G: Group; PACU: Post-anesthetic care unit; 
PO: per os; post-op: Postoperation.
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high- versus low-dose group up to 6 h after surgery, and signifi-
cantly lower than the no dose group up to 12 h, these results were 
not clinically meaningful. A 6-month telephone follow-up did not 
reveal any significant differences among groups in pain incidence 
or severity. The authors conclude that surgical procedures car-
ried out under general anesthesia alone using standard doses of 
opioids intraoperatively provide suboptimal protection from the 
injury barrage brought about by incision and subsequent noxious 
surgical events.
In another randomized, controlled, double-blind, study of 
141 women undergoing abdominal gynecological surgery by 
laparotomy, Katz et al. found that preincisional, but not postin-
cisional, administration of epidural lidocaine and fentanyl 
was associated with a significantly lower rate of morphine and 
reduced secondary mechanical hyperalgesia 48 h after surgery 
compared with a standard treatment group that received a sham 
epidural [197]. Follow-up at 3 weeks showed that pain disability 
ratings were significantly lower in the two groups that received 
the active epidural when compared with the standard treatment 
group, but no intergroup differences in pain, pain disability or 
general mental health were found at the 6-month follow-up [198]. 
Long-term pain after thyroidectomy
Brogly et al. evaluated the preventive effect of a single pre-
operative dose of gabapentin 1200 mg versus placebo in a rand-
omized, controlled, double-blind trial of 50 patients undergoing 
thyroidectomy under general anesthesia [199]. All patients received 
a bilateral superficial cervical plexus block with ropivacaine and 
clonidine after induction of the general anesthetic. Neither acute 
pain scores at rest, nor after swallowing, nor analgesic consump-
tion, differed significantly between the groups across the 24-h 
study period. However, 6 months after surgery, in a follow-up 
mail survey, the authors found that the incidence of neuropathic 
pain complaints was significantly lower in the patients that 
received preoperative gabapentin (4.3%) than placebo (29.2%). 
The delayed effect of gabapentin is difficult to explain in the 
absence of a similar effect in the acute postoperative period when 
the drug was active. The authors suggest that the absence of an 
early effect of gabapentin may have been masked by the bilateral 
superficial cervical plexus block. 
Long-term pain after major digestive surgery
Lavand’homme et al. randomly assigned 85 patients undergoing 
major digestive surgery to one of four groups to assess the pre-
ventive analgesic effects of administering a local anesthetic (lido-
caine or bupivacaine), an opioid (sufentanil or morphine) and an 
a
2
 adrenergic agonist (clonidine) by the intravenous or epidural 
route, before and/or after surgery under general anesthesia [200]. 
Patients received the three agents by the intravenous (Group 1) 
or epidural (Group 3) route before surgery and immediately after 
recovery for 72 h, the intravenous route followed the epidural 
route (Group 2) or the epidural route followed by the intravenous 
route (Group 4). All patients also received a bolus dose plus infu-
sion of low dose ketamine, which was started before incision and 
maintained throughout the procedure. Postoperative analgesics 
were delivered by an intravenous or epidural PCA pump. The 
results showed that across the 72-h study period, the number of 
patient-controlled requests for postoperative analgesia and pain 
scores at rest, after movement and after coughing were signifi-
cantly higher in Group 1 compared with the three other groups. 
The area of secondary mechanical hyperalgesia to punctuate 
stimulation surrounding the incision showed the same pattern 
of results: the groups that received the epidural, whether before, 
after, or before and after surgery, showed a smaller area of hyper-
algesia than the group that received the agents by the intravenous 
route before and after surgery. Patients were followed up by tel-
ephone and mail survey 2 weeks, 1, 6 and 12 months after surgery. 
The incidence of chronic postsurgical pain in Group 1 at the 6- 
(48%) and 12- (28%) month follow-ups was significantly greater 
than the zero incidence in Groups 3 and 4 at both time points. 
The 12-month results suggest a greater contribution to chronic 
pain of noxious intraoperative versus postoperative afferent input 
given the findings that the incidence of chronic pain in Group 2 
was neither different from that of Group 4 nor Group 1. Overall, 
the long-term results point to the importance of perioperative 
nociceptive blockade by the epidural route in preventing chronic 
postsurgical pain after major digestive surgery. 
Taken together, the results from the studies of preventive multi-
modal analgesia are equivocal. While there is some evidence that 
chronic postsurgical pain can be minimized or prevented by an 
analgesic approach involving aggressive perioperative multi modal 
treatment, other studies fail to show this benefit. A careful exami-
nation of these results raises several related issues that we must 
address, which are now discussed. 
The results show significant reductions in the incidence 
and/or mean intensity of long-term pain problems in some cases. 
However, a preventive analgesic approach does not work for every-
one and, at present, we do not know for whom such an approach 
is effective. One might assume that the mechanisms underlying 
the interindividual differences in efficacy of preventive analgesia 
is controlled genetically. When these determinants are identified, 
it might be possible to extend the efficacy of preventive analgesia 
for certain individuals.
We also do not know the mechanism(s) by which chronic post-
surgical pain is reduced when preventive analgesia is effective. 
The early pain relieving effects can be attributed to the pharma-
cological action of the agents used preventively; however, by defi-
nition [155,160,163] for studies that compare an active agent with a 
placebo control condition, preventive analgesia requires that the 
reduction in analgesic consumption and pain be observed at a point 
in time that exceeds the clinical duration of action of the target 
agent used preventively. This is meant to rule out the possibility 
that the observed effect is simply an analgesic effect. The typical 
explanation for a prolonged effect is that the agent(s) prevented 
(obtunded) the injury discharge, and/or peripheral and/or central 
sensitization and, thereby, reduced long-term pain. However, there 
really is very little good evidence that this is in fact the case, since 
we do not have accurate measures of sensitization in humans, and 
even if we did, this still would not indicate that reduction in sensi-
tization is responsible for the long-term reductions in pain incidence 
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and/or intensity. The longer the time from the administration of 
the analgesic agent(s), the greater the probability that other fac-
tors contribute to the long-term effects. For example, in discussing 
the effectiveness of peri operative epidural analgesia versus a sham 
epidural in reducing pain disability scores, but not pain intensity 
scores, 3 weeks after surgery [197], Katz and Cohen suggested that 
the reduced hyperalgesia and rate of morphine consumption within 
the first 2 days after surgery afforded the epidural groups a ‘head 
start’ in terms of comfort level and recovery compared with the 
sham epidural group, possibly increasing their self-efficacy in deal-
ing with pain or in mobilization [198]. A similar finding has been 
reported with respect to activity levels 3.5 weeks after radical retro-
pubic prostatectomy [187]. In that study, activity levels but not pain 
intensity were significantly higher in patients who had received 
pre-emptive epidural bupivacaine or fentanyl. Thus, the mecha-
nisms underlying preventive analgesia are probably more varied 
than currently acknowledged. 
We do not know why preventive analgesia does not work in 
some patients. One explanation that has not been investigated 
is that for some patients, the drug dose simply may not be large 
enough or changes in the kinetics or dynamics of the drug under 
investigation may have an impact on the results. Another pos-
sibility is that preoperative pain interferes with the effectiveness 
of preventive analgesia, perhaps because central sensitization 
has already been established [15,164,174,175]. Finally, genetic differ-
ences are also likely to play a role, in that study groups may have 
included a variable mixture of individuals susceptible or resist-
ant to the potential pre-emptive effect of the studied treatment, 
thereby masking a real effect. 
Chronic pain is a complex experience that manifests in several 
major domains, which include sensory–discriminative, affec-
tive–aversive and cognitive–evaluative. Each domain comprises 
several subdomains, for example, the sensory–discriminative 
domain consists of pain intensity (ranging from the lowest to 
Figure 3. Schematic illustration of the processes involved in the development of chronic postsurgical pain and pain 
disability showing relationships (arrows) among preoperative, intraoperative and postoperative factors. Lines with double 
arrows between variables show associative relationships reported in the literature. Lines with a single arrowhead show causal 
relationships based on randomized controlled trials of preventive analgesia. 
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the maximal; typical intensity), pain location (is it felt in the 
surgical field and/or can spread ‘extraterritorially’ to areas not 
innervated by injured nerves, can be felt as ‘mirror image’ pain 
on the contralateral intact side as well), pain quality (e.g., burn-
ing, crushing and electrical shock-like) and temporal (episodic 
or constant; if episodic, the frequency and duration of episodes 
is essential to document) subdomains. Similar breakdown into 
subdomains can be demonstrated for the affective–emotive and 
cognitive–evaluative dimensions. It is well established that parts 
of the brain that process sensory–discriminative aspects of the 
pain are largely separate from those that process affective–aversive 
aspects (e.g., S1 and S2 cortices and limbic areas, respectively). 
Moreover, each aspect largely engages unique biochemistry and 
targets for drugs including, presumably, those relevant for preven-
tive treatments. However, the main outcome measures in the vast 
majority of randomized controlled trials are simply pain inten-
sity and/or presence/absence of pain and analgesic use. While 
there is some correlation between pain intensity and the aver-
sive–affective aspects of the pain, this correlation is not very tight 
and the intensity cannot be taken as the sole parameter for the 
complex experience that pain is, especially when it has become 
chronic. It is rare to find a study that is more comprehensive in 
the outcome measures assessed. Of particular relevance to chronic 
postsurgical pain is the tendency for the anesthesia literature to 
focus on outcome measures of pain and analgesic use, and the 
psychological literature to focus on measures of pain disability 
or pain interference, making cross-study comparisons difficult. 
Recommendations for assessment of core measures and domains 
in clinical trials [201] include relevant psychological, emotional 
and physical–functional variables, in addition to those routinely 
assessed (i.e., pain and analgesic use). Assessment of additional 
domains of functioning may help to shed light on the predic-
tors of severe acute postoperative pain, the processes involved in 
recovery from surgery and the risk factors for developing chronic 
postsurgical pain [198]. 
Expert commentary
As depicted in Figure 3, the transition of acute postoperative pain to 
pathological chronic postsurgical pain is a complex developmental 
process involving biological, psychological and social-environ-
mental factors across the three phases of the peri operative period 
(preoperative, intraoperative and postoperative). The noxious 
effects of surgery (e.g., arising from incision, retraction, inflam-
matory response, ectopic activity following nerve injury and CNS 
reorganization into a centrally sensitized state), in conjunction 
with the competing, beneficial effects of peri operative, preventive 
multimodal analgesia, interact with pre-existing and concurrent 
pain, psychological and emotional factors (e.g., catastrophiz-
ing and pain coping strategies), as well as the social environ-
ment (e.g., solicitousness and social support) to determine the 
nature, severity, frequency and duration of chronic post surgical 
pain. Effectiveness of psychological management programs for 
other chronic pain problems is well established, but prevention 
and treatment efforts for chronic postsurgical pain have lagged 
behind. Development of a truly multimodal treatment regimen 
is essential, including not only modification of known surgical 
risk factors and protective pharmacotherapy, but also provision 
of perioperative psychological pain management programs aimed 
at preventing and treating chronic postsurgical pain. We are, at 
present, a long way from being able to predict with certainty who 
will recover uneventfully and who will go on to develop debilitat-
ing chronic pain. Finally, pain genetics carries the hope that such 
a reality can be achieved in our lifetime.
Five-year view
We do not expect significant gains to be made in the prevention 
of chronic postsurgical pain within the next 5 years. However, 
with the relatively recent introduction, and perioperative use, of 
the COX-2 inhibitors and the Ca
v
a
2
-d ligands, gabapentin and 
pregabalin, we may begin to see evidence of a reduction in the 
incidence and intensity of certain chronic postsurgical pains when 
used in combination with other agents in a balanced regimen of 
multimodal analgesia. Since these agents are available for oral 
administration, patients can be discharged with orders to continue 
to take them for several weeks after surgery, thus providing the 
opportunity for prolonged inhibition of the inflammatory cascade 
and suppression of ectopic activity. Both the COX-2 inhibitors 
and the Ca
v
a
2
-d ligands have been shown to produce clinically 
significant reductions in pain and opioid requirements in the acute 
postoperative setting and a logical extension would be to provide 
ongoing treatment with these agents to help minimize the transi-
tion to pain chronicity. We anticipate that some progress will be 
made in identifying heretofore unknown psychosocial predictors 
of chronic postsurgical pain and, hopefully, we will see the begin-
nings of psychological treatments aimed both at preventing chronic 
postsurgical pain and better managing it once it has developed. 
Clinically relevant behavioral mouse and rat models are available 
for the study of mechanisms underlying acute and chronic post-
surgical pain and they can be used as platforms for research and 
development of the next generation of analgesics, such as ralfina-
mide, that shows pre-emptive analgesic efficacy in rodent models. 
A very promising new research field that lags behind research into 
other human diseases is pain genetics. Powerful genetic assays 
are available to identify the genes controlling the interindividual 
variability in developing such pain types, as well as the variance in 
the efficacy of preventive and palliative analgesia. In the coming 
5 years, we should see the first signs of the ‘genetic revolution’ in 
pain medicine that will identify novel treatment targets.
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